Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Pfizer Inc. (NYSE:PFE)

Analysis of Solvency Ratios
Quarterly Data

Beginner level

Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.

Solvency Ratios (Summary)

Pfizer Inc., solvency ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Debt Ratios
Debt to equity 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77 0.66 0.58 0.58 0.56 0.61 0.72 0.75 0.75 0.71 0.70 0.70 0.62
Debt to capital 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43 0.40 0.37 0.37 0.36 0.38 0.42 0.43 0.43 0.41 0.41 0.41 0.38
Debt to assets 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29 0.26 0.24 0.25 0.25 0.25 0.26 0.26 0.26 0.25 0.25 0.26 0.24
Financial leverage 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64 2.51 2.35 2.36 2.25 2.41 2.83 2.89 2.89 2.88 2.82 2.72 2.58

Based on: 10-Q (filing date: 2021-05-13), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Pfizer Inc.’s debt to equity ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Pfizer Inc.’s debt to capital ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Pfizer Inc.’s debt to assets ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Pfizer Inc.’s financial leverage ratio decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Debt to Equity

Pfizer Inc., debt to equity calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt 4,352  2,703  13,363  13,084  16,007  16,195  16,617  10,507  9,410  8,831  7,385  11,583  9,010  9,953  9,448  9,514  7,680  10,688  13,633  13,724  11,546 
Long-term debt, excluding current portion 35,347  37,133  49,785  50,529  36,281  35,955  36,044  36,168  35,733  32,909  33,652  28,935  31,831  33,538  34,503  34,191  36,330  31,398  30,437  30,457  27,824 
Total debt 39,699  39,836  63,148  63,613  52,288  52,150  52,661  46,675  45,143  41,740  41,037  40,518  40,841  43,491  43,951  43,705  44,010  42,086  44,070  44,181  39,370 
 
Total Pfizer Inc. shareholders’ equity 68,620  63,238  65,259  64,336  65,026  63,143  65,103  59,568  58,806  63,407  71,319  69,778  73,184  71,308  60,770  58,368  58,435  59,544  63,306  62,769  63,067 
Solvency Ratio
Debt to equity1 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77 0.66 0.58 0.58 0.56 0.61 0.72 0.75 0.75 0.71 0.70 0.70 0.62
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. 6.24 6.58 5.70 5.94 — — — — — — — — 10.49 7.33 5.65 6.20 7.39 7.95 5.77 6.71 6.87
Amgen Inc. 3.50 3.51 3.13 3.21 3.36 3.09 2.73 2.84 3.05 2.71 2.40 2.31 2.28 1.40 1.11 1.11 1.11 1.16 1.15 1.10 1.20
Eli Lilly & Co. 2.35 2.94 3.51 3.99 5.60 5.88 4.50 5.68 6.44 1.30 0.97 1.06 0.81 1.18 0.90 0.87 0.73 0.74 0.60 0.64 0.54
Gilead Sciences Inc. 1.59 1.73 1.68 1.34 1.09 1.09 1.19 1.15 1.21 1.28 1.19 1.34 1.41 1.64 1.18 1.16 1.29 1.39 1.60 1.42 1.70
Illumina Inc. 0.44 0.25 0.25 0.25 0.25 0.25 0.25 0.26 0.44 0.53 0.57 0.42 0.45 0.49 0.46 0.48 0.49 0.58 0.54 0.50 0.51
Johnson & Johnson 0.51 0.56 0.59 0.48 0.45 0.47 0.50 0.48 0.50 0.51 0.48 0.51 0.51 0.57 0.48 0.48 0.46 0.39 0.37 0.36 0.32
Merck & Co. Inc. 1.16 1.26 0.98 1.12 1.07 1.02 0.97 0.96 0.94 0.94 0.73 0.72 0.70 0.71 0.71 0.63 0.71 0.62 0.57 0.56 0.59
Regeneron Pharmaceuticals Inc. 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08 0.08 0.09 0.10 0.11 0.11 0.12 0.13 0.15 0.11 0.09 0.09 0.10
Thermo Fisher Scientific Inc. 0.53 0.63 0.66 0.71 0.70 0.60 0.58 0.66 0.66 0.69 0.70 0.73 0.80 0.83 0.89 0.75 0.78 0.77 0.87 0.67 0.72
Zoetis Inc. 1.76 1.91 2.14 2.58 2.35 2.38 2.41 2.67 2.78 2.95 3.04 2.52 2.53 2.80 2.87 2.66 2.78 3.00 2.82 3.29 3.84

Based on: 10-Q (filing date: 2021-05-13), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q1 2021 Calculation
Debt to equity = Total debt ÷ Total Pfizer Inc. shareholders’ equity
= 39,699 ÷ 68,620 = 0.58

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Pfizer Inc.’s debt to equity ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Debt to Capital

Pfizer Inc., debt to capital calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt 4,352  2,703  13,363  13,084  16,007  16,195  16,617  10,507  9,410  8,831  7,385  11,583  9,010  9,953  9,448  9,514  7,680  10,688  13,633  13,724  11,546 
Long-term debt, excluding current portion 35,347  37,133  49,785  50,529  36,281  35,955  36,044  36,168  35,733  32,909  33,652  28,935  31,831  33,538  34,503  34,191  36,330  31,398  30,437  30,457  27,824 
Total debt 39,699  39,836  63,148  63,613  52,288  52,150  52,661  46,675  45,143  41,740  41,037  40,518  40,841  43,491  43,951  43,705  44,010  42,086  44,070  44,181  39,370 
Total Pfizer Inc. shareholders’ equity 68,620  63,238  65,259  64,336  65,026  63,143  65,103  59,568  58,806  63,407  71,319  69,778  73,184  71,308  60,770  58,368  58,435  59,544  63,306  62,769  63,067 
Total capital 108,319  103,074  128,407  127,949  117,314  115,293  117,764  106,243  103,949  105,147  112,356  110,296  114,025  114,799  104,721  102,073  102,445  101,630  107,376  106,950  102,437 
Solvency Ratio
Debt to capital1 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43 0.40 0.37 0.37 0.36 0.38 0.42 0.43 0.43 0.41 0.41 0.41 0.38
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 0.86 0.87 0.85 0.86 1.12 1.14 1.27 1.30 1.27 1.27 1.08 1.10 0.91 0.88 0.85 0.86 0.88 0.89 0.85 0.87 0.87
Amgen Inc. 0.78 0.78 0.76 0.76 0.77 0.76 0.73 0.74 0.75 0.73 0.71 0.70 0.69 0.58 0.53 0.53 0.53 0.54 0.53 0.52 0.54
Eli Lilly & Co. 0.70 0.75 0.78 0.80 0.85 0.85 0.82 0.85 0.87 0.57 0.49 0.51 0.45 0.54 0.47 0.47 0.42 0.42 0.37 0.39 0.35
Gilead Sciences Inc. 0.61 0.63 0.63 0.57 0.52 0.52 0.54 0.54 0.55 0.56 0.54 0.57 0.59 0.62 0.54 0.54 0.56 0.58 0.62 0.59 0.63
Illumina Inc. 0.30 0.20 0.20 0.20 0.20 0.20 0.20 0.21 0.30 0.35 0.36 0.30 0.31 0.33 0.31 0.32 0.33 0.37 0.35 0.33 0.34
Johnson & Johnson 0.34 0.36 0.37 0.33 0.31 0.32 0.33 0.33 0.33 0.34 0.33 0.34 0.34 0.37 0.32 0.32 0.32 0.28 0.27 0.27 0.24
Merck & Co. Inc. 0.54 0.56 0.50 0.53 0.52 0.50 0.49 0.49 0.48 0.48 0.42 0.42 0.41 0.42 0.41 0.39 0.42 0.38 0.36 0.36 0.37
Regeneron Pharmaceuticals Inc. 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07 0.07 0.08 0.09 0.10 0.10 0.10 0.11 0.13 0.10 0.08 0.08 0.09
Thermo Fisher Scientific Inc. 0.35 0.39 0.40 0.42 0.41 0.37 0.37 0.40 0.40 0.41 0.41 0.42 0.44 0.45 0.47 0.43 0.44 0.44 0.47 0.40 0.42
Zoetis Inc. 0.64 0.66 0.68 0.72 0.70 0.70 0.71 0.73 0.74 0.75 0.75 0.72 0.72 0.74 0.74 0.73 0.74 0.75 0.74 0.77 0.79

Based on: 10-Q (filing date: 2021-05-13), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q1 2021 Calculation
Debt to capital = Total debt ÷ Total capital
= 39,699 ÷ 108,319 = 0.37

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Pfizer Inc.’s debt to capital ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Debt to Assets

Pfizer Inc., debt to assets calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt 4,352  2,703  13,363  13,084  16,007  16,195  16,617  10,507  9,410  8,831  7,385  11,583  9,010  9,953  9,448  9,514  7,680  10,688  13,633  13,724  11,546 
Long-term debt, excluding current portion 35,347  37,133  49,785  50,529  36,281  35,955  36,044  36,168  35,733  32,909  33,652  28,935  31,831  33,538  34,503  34,191  36,330  31,398  30,437  30,457  27,824 
Total debt 39,699  39,836  63,148  63,613  52,288  52,150  52,661  46,675  45,143  41,740  41,037  40,518  40,841  43,491  43,951  43,705  44,010  42,086  44,070  44,181  39,370 
 
Total assets 158,818  154,229  178,983  177,934  166,336  167,489  170,446  156,199  155,421  159,422  167,838  164,980  164,612  171,797  172,151  168,558  168,784  171,615  178,430  170,658  162,929 
Solvency Ratio
Debt to assets1 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29 0.26 0.24 0.25 0.25 0.25 0.26 0.26 0.26 0.25 0.25 0.26 0.24
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.57 0.57 0.58 0.58 0.74 0.75 0.65 0.65 0.65 0.68 0.61 0.60 0.54 0.53 0.55 0.56 0.56 0.56 0.56 0.56 0.59
Amgen Inc. 0.52 0.52 0.53 0.53 0.52 0.50 0.50 0.52 0.52 0.51 0.51 0.51 0.50 0.44 0.45 0.44 0.44 0.45 0.45 0.44 0.46
Eli Lilly & Co. 0.35 0.36 0.39 0.39 0.42 0.39 0.40 0.41 0.42 0.29 0.28 0.29 0.26 0.30 0.31 0.30 0.27 0.27 0.25 0.26 0.23
Gilead Sciences Inc. 0.45 0.46 0.48 0.43 0.40 0.40 0.42 0.41 0.42 0.43 0.42 0.44 0.44 0.48 0.45 0.44 0.46 0.46 0.48 0.44 0.48
Illumina Inc. 0.25 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.24 0.29 0.29 0.23 0.24 0.25 0.26 0.27 0.27 0.30 0.29 0.26 0.27
Johnson & Johnson 0.19 0.20 0.22 0.19 0.18 0.18 0.19 0.19 0.20 0.20 0.20 0.21 0.21 0.22 0.23 0.23 0.22 0.19 0.19 0.19 0.17
Merck & Co. Inc. 0.34 0.35 0.32 0.34 0.33 0.31 0.31 0.32 0.31 0.30 0.28 0.27 0.27 0.28 0.29 0.27 0.29 0.26 0.26 0.25 0.26
Regeneron Pharmaceuticals Inc. 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.07 0.06 0.06 0.06
Thermo Fisher Scientific Inc. 0.28 0.31 0.33 0.35 0.34 0.30 0.30 0.33 0.33 0.34 0.34 0.35 0.37 0.37 0.39 0.36 0.37 0.36 0.39 0.33 0.35
Zoetis Inc. 0.52 0.53 0.56 0.59 0.56 0.56 0.57 0.59 0.59 0.60 0.62 0.58 0.57 0.58 0.61 0.59 0.58 0.58 0.58 0.59 0.60

Based on: 10-Q (filing date: 2021-05-13), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q1 2021 Calculation
Debt to assets = Total debt ÷ Total assets
= 39,699 ÷ 158,818 = 0.25

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Pfizer Inc.’s debt to assets ratio improved from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Financial Leverage

Pfizer Inc., financial leverage calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Total assets 158,818  154,229  178,983  177,934  166,336  167,489  170,446  156,199  155,421  159,422  167,838  164,980  164,612  171,797  172,151  168,558  168,784  171,615  178,430  170,658  162,929 
Total Pfizer Inc. shareholders’ equity 68,620  63,238  65,259  64,336  65,026  63,143  65,103  59,568  58,806  63,407  71,319  69,778  73,184  71,308  60,770  58,368  58,435  59,544  63,306  62,769  63,067 
Solvency Ratio
Financial leverage1 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64 2.51 2.35 2.36 2.25 2.41 2.83 2.89 2.89 2.88 2.82 2.72 2.58
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. 10.98 11.51 9.80 10.17 — — — — — — — — 19.52 13.89 10.29 11.15 13.14 14.26 10.30 11.92 11.57
Amgen Inc. 6.70 6.69 5.90 6.10 6.50 6.17 5.45 5.50 5.91 5.31 4.69 4.54 4.56 3.17 2.49 2.51 2.54 2.60 2.54 2.50 2.62
Eli Lilly & Co. 6.79 8.27 9.10 10.25 13.35 15.07 11.20 13.91 15.32 4.47 3.41 3.67 3.05 3.88 2.89 2.90 2.68 2.77 2.41 2.49 2.31
Gilead Sciences Inc. 3.56 3.76 3.49 3.10 2.71 2.74 2.87 2.79 2.86 2.98 2.81 3.02 3.18 3.44 2.60 2.66 2.82 3.02 3.36 3.22 3.57
Illumina Inc. 1.78 1.62 1.58 1.59 1.57 1.59 1.60 1.61 1.85 1.85 1.93 1.80 1.84 1.91 1.77 1.79 1.80 1.95 1.89 1.94 1.91
Johnson & Johnson 2.62 2.76 2.65 2.51 2.53 2.65 2.67 2.55 2.54 2.56 2.41 2.47 2.48 2.61 2.10 2.12 2.06 2.01 1.93 1.93 1.88
Merck & Co. Inc. 3.37 3.62 3.08 3.28 3.24 3.26 3.10 3.04 2.99 3.09 2.63 2.61 2.56 2.56 2.40 2.35 2.42 2.38 2.25 2.23 2.25
Regeneron Pharmaceuticals Inc. 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36 1.34 1.37 1.38 1.43 1.43 1.44 1.47 1.61 1.57 1.52 1.52 1.57
Thermo Fisher Scientific Inc. 1.88 2.00 2.01 2.06 2.05 1.97 1.93 2.02 2.01 2.04 2.05 2.10 2.17 2.23 2.27 2.08 2.12 2.13 2.22 1.99 2.05
Zoetis Inc. 3.37 3.61 3.81 4.38 4.19 4.26 4.21 4.56 4.70 4.93 4.94 4.37 4.43 4.85 4.67 4.55 4.75 5.14 4.87 5.54 6.40

Based on: 10-Q (filing date: 2021-05-13), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q1 2021 Calculation
Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= 158,818 ÷ 68,620 = 2.31

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Pfizer Inc.’s financial leverage ratio decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.